AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 81 min read$RMD

Farrell Michael J. sold $1.1M of RMD

Farrell Michael J. (Chairman and CEO) sold 4,991 shares of RESMED INC (RMD) at $226.33 ($1.13M total) on 2026-10-07 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Farrell Michael J.
Published Oct 8, 2026, 9:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 9:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RMD
Bearish
medium confidence
Mentioned
$RMD
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RMDBearishLow
01

Why it matters

The sale reduces insider ownership and may be interpreted as a negative signal, but the size is modest relative to total holdings.

02

Market read

A modest insider sell by the CEO, disclosed via Form 4, provides a low‑to‑moderate trading signal.

03

What to watch

Potential upcoming earnings or product news that may offset the sell‑off.

Relevance 5/10Novelty 5/10Timing: after-hours filing today

Background

Form 4 filings are primary disclosures of insider transactions required by the SEC.

Company-level read

Ticker impact

$RMDBearishMedium confidence
Context

CEO Michael J. Farrell sold 4,991 shares for $1.13M via a 10b5‑1 plan, reducing his stake to 479,803 shares.

Expected impact

likely downward pressure as the market prices in the insider sell

Evidence & confidence

A $1.1M sale by the chairman/CEO is material but not large enough to trigger a sharp move; traders may watch for short‑term weakness.

Market effects

Sector

Minimal impact on the broader medical device sector; insider activity is company‑specific.

Regional

No regional effect; the filing is U.S.‑focused.

Global

Low global relevance.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to fundamentals.

Key entities

  • Person
    Michael J. Farrell

    Chairman and CEO of ResMed Inc.

  • Company
    ResMed Inc.

    Medical device manufacturer listed on NYSE.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RMD insider trading history →

Related articles

SEP 28
$RMDMed

Health Check: No 'Wharfie Time' curse as healthcare stocks kick away from the pack

ASX healthcare stocks, led by CSL (ASX:CSL) and ResMed (ASX:RMD), gained institutional investor interest, with Morgan Stanley noting increased overweight positions. RBC Capital upgraded several healthcare stocks, citing better-than-expected earnings. Healius (ASX:HLS) plans to sell Agilex for $160M to Novotech, addressing balance sheet challenges. Paradigm Biopharmaceuticals (ASX:PAR) delayed its trading resumption to address financial matters.

stockhead.com.au5 min
SEP 16
$RMDMed

CSL, Resmed, and more. See which ASX health stocks RBC Capital Markets has upgraded

RBC Capital Markets upgraded five ASX-listed healthcare stocks to outperform, citing positive earnings growth and attractive valuations. CSL (ASX: CSL) was highlighted for market share gains, with a $213 price target. ResMed (ASX: RMD) was noted for capital management, with a $262 target. Ramsay Healthcare (ASX: RHC) was praised for cost control, with a $68 target. Fisher & Paykel (ASX: FPH) showed strong growth, with a $52 target. Nanosonics (ASX: NAN) had mixed results but a $3.75 target.

fool.com.au2 min
SEP 16
$RMDMed

ResMed Shares Jump Following RBC Capital Upgrade to Outperform

ResMed (RMD) stock rose 3% after RBC Capital upgraded it to Outperform, raising the price target to $262. Analyst Craig Wong-Pan cited strong growth in sleep devices, both in the Americas and internationally, and projected high single-digit EPS growth over three years. The FDA's recall of a competing device also boosted sentiment.

tikr.com2 min
SEP 15
$RMDHighAI 8/10

Why is ResMed stock rallying today?

ResMed (RMD) stock rose 2.9% after providing fiscal 2027 guidance, projecting 5%-7% revenue growth and 12%-14% EPS growth. RBC upgraded RMD to Outperform, raising its price target to $262. Despite broader market declines, RMD's positive outlook resonated with investors, addressing concerns about GLP-1 headwinds and competition.

investing.com2 min